APG-1387

DB16095InvestigationalSmall molecule

APG-1387 is under investigation in clinical trial NCT04568265 (A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B).

Formula / weight: C₆₀H₇₂N₁₀O₁₀S₂ · 1157.42 g/mol (avg)
Also known as: Apg-1387 (smac mimetic)
Code names: APG-1387 · SM-1387

Resolves to

Compound

UNIIE53VN70K2XCAS1570231-89-8

Structure

InChIKeyAKLBERUGKZNEJY-RTEPGWBGSA-NSMILES

[H][C@]12CC[C@H](N1C(=O)[C@H](CN(CC2)S(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)N1CC[C@@]2([H])CC[C@H](N2C(=O)[C@H](C1)NC(=O)[C@H](C)NC)C(=O)NC(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)[C@H](C)NC)C(=O)NC(C1=CC=CC=C1)C1=CC=CC=C1

Targets

O15392BIRC5Q96CA5BIRC7Q13075NAIPQ13489BIRC3Q13490BIRC2P98170XIAP

What you can answer from here — as of October 29, 2025

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with APG-1387, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account